Table 1.
Clinical description of patient cohort
| Total (n = 300) | Pso (n = 111) | PsA (n = 189) | p value | |
|---|---|---|---|---|
| Age, years, mean (SD) | 54.3 (14.5) | 51.0 (16.0) | 56.2 (13.3) | 0.005 |
| Male, n (%)/female, n (%) | 162 (54.0%)/138 (46.0%) | 55 (49.5%)/56 (50.5%) | 107 (56.6%)/82 (43.4%) | 0.236 |
| BMI, kg/m2, mean (SD) (n = 274) | 27.8 (5.65) | 28.2 (6.29) | 27.6 (5.29) | 0.413 |
| Smokers, n (%) (n = 243) | 80 (32.9%) | 43 (57.3%) | 37 (22.0%) | < 0.001 |
| Disease duration, years, mean (SD) (n = 266) | 15.4 (12.5) | 17.4 (14.1) | 14.0 (11.2) | 0.035 |
| DAS28, mean (SD) | NA | NA | 2.51 (1.01) | NA |
| CRP, mean (SD) | 6.18 (7.17) | 5.01 (3.68) | 6.82 (8.43) | 0.016 |
| Highest educational degree | ||||
| Postgraduate, n (%) | 5 (1.7) | 0 (0.0) | 5 (2.7) | 0.170 |
| University degree, n (%) | 18 (6.0) | 8 (7.3) | 10 (5.3) | |
| Polytechnic degree, n (%) | 19 (6.4) | 7 (6.4) | 12 (6.4) | |
| High school diploma (Abitur), n (%) | 15 (5.0) | 4 (3.6) | 11 (5.9) | |
| Polytechnic entrance qualification, n (%) | 20 (6.7) | 5 (4.5) | 15 (8.0) | |
| Intermediate school certificate, n (%) | 93 (31.2) | 34 (30.9) | 59 (31.4) | |
| Lower secondary education, n (%) | 120 (40.3) | 46 (41.8) | 74 (39.4) | |
| No degree, n (%) | 8 (2.7) | 6 (5.5) | 2 (1.1) | |
| Therapy | ||||
| Topical, n (%) | 38 (12.7) | 35 (31.5) | 3 (1.6) | < 0.001 |
| Systemic, n (%) | 232 (77.3) | 76 (68.5) | 156 (82.5) | 0.005 |
| csDMARD, n (%) | 87 (29.0) | 8 (7.2) | 79 (41.8) | < 0.001 |
| bDMARD, n (%) | 154 (53.3) | 46 (41.4) | 108 (60.7) | 0.001 |
| tsDMARD, n (%) | 23 (7.7) | 10 (9.0) | 13 (6.9) | 0.503 |
| Combination b/tsDMARD + csDMARD, n (%) | 48 (16.0) | 1 (0.9) | 47 (24.9) | < 0.001 |
| NSAID monotherapy, n (%) | 3 (1.0) | 0 (0.0) | 3 (1.6) | 0.182 |
For parameters for which data from individual patients were missing, the number (n) for the individual item is given in the first column
bDMARD biological disease-modifying antirheumatic drug, BMI body mass index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, n number, NA not available, NSAID non-steroidal anti-inflammatory drugs, PsA psoriatic arthritis, Pso psoriasis, SD standard deviation, tsDMARD targeted synthetic disease-modifying antirheumatic drug